KRAS and cancer: NSC-743380 is highly active (median growth inhibitory concentration [IC50] between 10 nM and 1 M) in vitro in 30 of 102 cancer cell lines tested [20, 25], including many KRAS mutant cancer cells [19, 21, 25].